IDEXX Laboratories, Inc. IDXX
672.04 USD +0.40 (+0.06%)
At closeNov 3, 2026, 6:31 PM EST
672.04 0.00 0.00%
After hours · Nov 3, 6:31 PM ET
655.52 Day range 681.50
500.61 52-week range 769.98
- YTD
- -0.66%
- 1 year
- -7.04%
Analyst view
Consensus: buy
Buy
Price target (mean) 705.92 +5.0% upside
Now 672.04
- Target (low)
- 470.00
- Target (mean)
- 705.92
- Target (high)
- 810.00
Ratings (0m) 14 9 buy · 4 hold · 1 sell
- Strong buy4
- Buy5
- Hold4
- Sell1
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 13
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 3.71 | 3.37 – 3.91 | 3.08 | +20.6% | 1.18B | +8.5% | 10 |
| Next quarter | 3.97 | 3.88 – 4.03 | 3.08 | +28.9% | 1.23B | +7.4% | 9 |
| Current year | 14.93 | 14.60 – 15.09 | 13.08 | +14.2% | 4.76B | +10.5% | 11 |
| Next year | 16.81 | 16.07 – 17.15 | 14.93 | +12.6% | 5.17B | +8.6% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 3, 2026 | UBS | Maintained | Neutral | Neutral |
| Oct 27, 2026 | UBS | Maintained | Neutral | Neutral |
| Oct 16, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 12, 2026 | Keybanc | Initiated | — | Sector Weight |
| Aug 11, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 5, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 5, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Jul 27, 2026 | UBS | Maintained | Neutral | Neutral |
| Apr 28, 2026 | UBS | Maintained | Neutral | Neutral |
| Apr 15, 2026 | Citigroup | Initiated | — | Neutral |
| Mar 31, 2026 | Stifel | Maintained | Buy | Buy |
| Feb 9, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Feb 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 3, 2026 | UBS | Maintained | Neutral | Neutral |
| Feb 3, 2026 | BTIG | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Nov 4, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 4, 2025 | UBS | Maintained | Neutral | Neutral |
| Nov 4, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 4, 2025 | BTIG | Maintained | Buy | Buy |
| Oct 31, 2025 | Stifel | Upgrade | Hold | Buy |
| Oct 1, 2025 | UBS | Initiated | — | Neutral |
| Aug 15, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 11, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Aug 4, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 4, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 29, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 17, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Jul 2, 2025 | Stifel | Maintained | Hold | Hold |
